NovoMedix, LLC is a pre-clinical stage biopharmaceutical company that discovers and develops small molecule therapeutics that target key regulatory pathways in life-threatening diseases. Our lead drug candidates inhibit IL-11 expression, which is an emerging and critical target for cancer, fibrosis, and metabolic diseases. Unlike other potential IL-11 inhibitors under development, such as antibodies, our inhibitors are orally available, inexpensive to manufacture, and stable at room temperature. These small molecule drug candidates have demonstrated efficacy in animal models of liver, lung, and cardiac fibrosis; in prevention of tumor growth and metastasis and prevention of chemotherapy induced cardiotoxicity in triple negative breast cancer (TNBC); and in improvement in glucose homeostasis in diabetes. Our initial focus is treatment and prevention of cardiotoxicity in TNBC and we are poised to begin IND enabling studies.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2001
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Drug candidate for TNBC
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
